Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Acute or severe anxiety; Aggression; Agitation; Impulsive behaviour Initial: 15-30 mg/day in 2 divided doses. Schizophrenia; Severe psychoses Initial: 75 mg/day in divided doses. Increase slowly if needed. Max maintenance: 300 mg/day.
Dosage Details
Severe psychoses, Schizophrenia
Adult: Initially, 75 mg daily in divided doses. Increase if necessary at wkly intervals by 25 mg until optimum effect is achieved. Max maintenance: 300 mg/day.
Child: >1 yr: Initially, 500 mcg daily for a 10-kg child and increase by 1 mg for each additional 5 kg to a max total of 10 mg daily. Dose may be gradually increased according to response. Maintenance: Do not exceed twice the initial daily dose.
Elderly: Initially, 15-30 mg daily in divided doses.

Acute anxiety, Aggression, Agitation, Impulsive behaviour
Adult: Initially, 15-30 mg daily in 2 divided doses adjusted according to response. The larger dose taken at night.
Elderly: Initially, 5-10 mg daily in divided doses.
Severe CNS depression; subcortical brain damage; hepatic impairment; circulatory collapse; bone marrow suppression and blood dyscrasias; coma.
Special Precautions
Renal or respiratory impairment, Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis, prostatic hypertrophy. Narrow-angle glaucoma or agranulocytosis. Elderly. History of seizures. Dehydration. Monitor blood counts. Withdraw gradually. Bradycardia, congenital or acquired QT prolongation; hypokalaemia, hypocalcaemia or hypomagnesaemia; alcohol abuse. Stroke risk factors. Prolactin-dependent tumours. Avoid exposure to direct sunlight. Avoid contact with the skin. May impair ability to drive or operate machinery. Pregnancy and lactation.
Adverse Reactions
AV block, ECG changes, oedema, hypotension, QTc prolongation, syncope, tachycardia; aggressive behaviour, agitation, anxiety, depression, dizziness, drowsiness, EEG changes, excitement; extrapyramidal symptoms; fatigue, fever, headache, insomnia, restlessness, seizure, sleep disturbance; photosensitivity, pruritus, rash, urticaria; changes in appetite, galactorrhoea, gynaecomastia, libido changes, menstrual irregularities, wt changes; adynamic ileus, constipation, nausea, vomiting, xerostomia; impotence, incontinence, urinary retention; cholestasis, jaundice; blurred vision, glaucoma, lenticular deposits; nasal congestion, pneumonia, pneumonitis; diaphoresis.
Potentially Fatal: Cardiac arrest, neuroleptic malignant syndrome, blood dyscrasias.
Symptoms: Deep sleep, coma, extrapyramidal symptoms, abnormal involuntary muscle movements, hypotension, arrhythmias. Management: Symptomatic and supportive. Avoid use of medications that also prolong the QTc interval. Parenteral inotropic agents may be required (e.g. norepinephrine); do not use epinephrine or dopamine.
Drug Interactions
Exaggerated response to α-adrenoceptor blockers. Additive anticholinergic effects with other anticholinergic drugs. May reduce effects of amphetamine, clonidine, guanethidine, adrenaline. Absorption may be affected by antacids, anti-Parkinson drugs, lithium. High doses may reduce the response to hypoglycaemic agents. Neurotoxicity may occur with lithium. Transient metabolic encephalopathy may occur with desferrioxamine. Increased risk of agranulocytosis with carbamazepine or certain antibiotics and cytotoxics.
Potentially Fatal: Additive CNS depression with alcohol, barbiturates and other sedatives. Increased risk of arrhythmias with QT prolonging drugs (e.g. certain antiarrhythmics, antidepressants, other antipsychotics) and drugs causing electrolyte imbalance. May reduce effects of levodopa.
Food Interaction
Increased CNS depression with kava kava, valerian, St John's wort, gotu kola. Dong quai, St John's wort may also cause photosensitisation). Smoking may reduce serum levels of periciazine.
Lab Interference
Phenothiazines may cause false-positive pregnancy tests.
Description: Periciazine is a phenothiazine antipsychotic.
Store at 20-25°C (68-77°). Protect from light.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Periciazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in